Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity-Reference-Cited by-同舟云学术

Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity

Published:2020-03-09 Issue:6 Volume:63 Page:3047-3065
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Serafini Marta¹,Torre Enza¹,Aprile Silvio¹^ORCID,Grosso Erika Del¹,Gesù Alessandro¹,Griglio Alessia¹,Colombo Giorgia¹,Travelli Cristina²,Paiella Salvatore³,Adamo Annalisa⁴,Orecchini Elena⁵,Coletti Alice⁶,Pallotta Maria Teresa⁵,Ugel Stefano⁴,Massarotti Alberto¹^ORCID,Pirali Tracey¹^ORCID,Fallarini Silvia¹

Affiliation:

1. Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara 28100, Italy

2. Department of Pharmaceutical Sciences, Università degli Studi di Pavia, Pavia 27100, Italy

3. General and Pancreatic Surgery, Pancreas Institute, University of Verona, Verona 37134, Italy

4. University Hospital and Department of Medicine, Section of Immunology, University of Verona, Verona37126, Italy

5. Department of Experimental Medicine, University of Perugia, Perugia 06132, Italy

6. Department of Medicine, University of Perugia, Piazza Lucio Severi 1, Perugia 06132, Italy

Funder

Ministero dell?Istruzione, dell?Universit? e della Ricerca

Associazione Italiana per la Ricerca sul Cancro

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01809

Reference82 articles.

1. Cancer immunotherapy using checkpoint blockade

2. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Pembrolizumab versus Ipilimumab in Advanced Melanoma

5. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of 2-benzylsulfinyl-benzoxazoles as potent and selective indoleamine 2,3-dioxygenase 1 inhibitors to combat inflammation;Bioorganic Chemistry;2024-11

2. Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1;ACS Pharmacology & Translational Science;2024-09-12

3. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

4. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC;Frontiers in Immunology;2024-05-16

5. Recent Progress in the Synthesis and Biological Assessment of Benzimidazole-1,2,3- Triazole Hybrids;Current Organic Chemistry;2024-05